Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-486 + Venetoclax in AML
NCT04887857Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of CC-486 in acute myeloid leukemia (AML), sponsored by Celgene Corporation. Primary endpoints: Maximum Tolerated Dose at 42 days, Incidence of Adverse Events and 1 more. Started Dec 2021; status: completed.
02
Drugs
CC-486
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04887857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04887857.